FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Jazz Plans sNDA for Zepzelca in Lung Cancer

[ Price : $8.95]

Jazz Pharmaceuticals plans to file a supplemental NDA next year following positive top-line results from its Phase 3 clinical tria...

CDER, CBER Working on START Trial Support Program

[ Price : $8.95]

CDER director Patrizia Cavazzoni says the Center worked with CBER to launch in 2023 the START program, providing selected particip...

CDER Drug Shortage Management Process

[ Price : $8.95]

FDA posts a consumer-focused explanation of how CDER determines and manages drug shortages.

CDRH Pilots Trial Participation Snapshots

[ Price : $8.95]

CDRH pilots medical device trial participation snapshots to provide key information about clinical trials that supported their app...

FDA on Curbing X-ray Device Interference

[ Price : $8.95]

FDA makes recommendations to prevent damage to wearable medical devices from X-ray imaging, including CT scans.

CGMP Violations at Outin Futures

[ Price : $8.95]

FDA warns Koreas Outin Futures Corp. about CGMP and misbranding violations at its drug manufacturing facility.

Noxafil Not Withdrawn Over Safety/Efficacy

[ Price : $8.95]

Federal Register notice: FDA determines that Merck Sharp & Dohmes Noxafil (posaconazole) 100g delayed-release tablets were not wit...

IntraBio Wins Priority Voucher for Aqneursa Approval

[ Price : $8.95]

Federal Register notice: FDA issues IntraBio a priority review voucher after determining its recent approval of Aqneursa (levacety...

14 Observations in Qualgen FDA-483

[ Price : $8.95]

FDA releases the form FDA-483 with 14 observations issued following an inspection at the Edmond, OK-based Qualgen outsourcing faci...

FDA Clears AI-Interpreting Echocardiography Software

[ Price : $8.95]

FDA clears an iCardio.ai 510(k) for its artificial intelligence software EchoMeasure for interpreting echocardiography.